GeorgeJHannaMD(He/Him)

PubMed

• 1 citations
  The Influence of Social Determinants on Receiving Outpatient Treatment with Monoclonal Antibodies, Disease Risk, and Effectiveness for COVID-19.
  O'Horo, J. C., Nalini Ambrose, Alpesh Amin, Brian Anderson, Monica Bertagnolli, Francis Campion, Dan Chow, Risa Danan, Lauren D'Arinzo, Ashley Drews, Karl Erlandson, K...> ;Journal of General Internal Medicine. 2023 Dec 1
• 5 citations
  Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.
  Stewart, T., Rebolledo, P., Mourad, A., Lindsell, C., Boulware, D., McCarthy, M., Thicklin, F., Garcia Del Sol, I., Bramante, C., Lenert, L., Lim, S., Williamson, J., ...> ;JAMA. 2023 Dec 26
• 1 citations
  Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19.
  David R Boulware, Christopher J Lindsell, Thomas G Stewart, Adrian F Hernandez, Sean Collins, Matthew William McCarthy, Dushyantha Jayaweera, Nina Gentile, Mario Castr...> ;The New England Journal of Medicine. 2023 Sep 21
• 4 citations
  Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes.
  Nalini Ambrose, Alpesh Amin, Brian Anderson, Julio Barrera-Oro, Monica Bertagnolli, Francis Campion, Daniel Chow, Risa Danan, Lauren D'Arinzo, Ashley Drews, Karl Erlan...> ;JAMA Network Open. 2023 Apr 3
• 30 citations
  Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
  Matthew W McCarthy, Susanna Naggie, David R Boulware, Christopher J Lindsell, Thomas G Stewart, G Michael Felker, Dushyantha Jayaweera, Mark Sulkowski, Nina Gentile, C...> ;JAMA. 2023 Jan 24
• 25 citations
  Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.
  Susanna Naggie, David R Boulware, Christopher J Lindsell, Thomas G Stewart, Alex J Slandzicki, Stephen C Lim, Jonathan Cohen, David Kavtaradze, Arch P Amon, Ahab Gabri...> ;JAMA. 2023 Mar 21
• 40 citations
  Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
  Susanna Naggie, David R Boulware, Christopher J Lindsell, Thomas G Stewart, Nina Gentile, Sean Collins, Matthew William McCarthy, Dushyantha Jayaweera, Mario Castro, M...> ;JAMA. 2022 Oct 25
• 31 citations
  Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infecti...
  Chloe Orkin, Kathleen Squires, Jean-Michel Molina, Paul E. Sax, Otto Sussmann, Gina Lin, Sushma Kumar, George J. Hanna, Carey Hwang, Elizabeth Martin, Hedy Teppler> ;Clinical Infectious Diseases. 2020 Dec 18
• 16 citations
  Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Tra...
  Alexander Wong, Deborah Goldstein, Josep Mallolas, Edwin DeJesus, Margaret A. Johnson, Jean-Michel Molina, Anton Pozniak, Anthony Rodgers, Valerie L Teal, Deborah A. H...> ;Journal of Acquired Immune Deficiency Syndromes. 2019 Dec 1
• 10 citations
  Evaluation of Neural Tube Defects (NTDs) After Exposure to Raltegravir During Pregnancy.
  Hala Shamsuddin, Casey Raudenbush, Brittany L Sciba, Yun-Ping Zhou, T. Christopher Mast, Wayne Greaves, George J. Hanna, Ronald W Leong, Walter L. Straus> ;Journal of Acquired Immune Deficiency Syndromes. 2019 Jul 1
• 15 citations
  Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results F...
  Pedro Cahn, Paul E. Sax, Kathleen Squires, Jean-Michel Molina, Winai Ratanasuwan, Mohammed Rassool, Mark Bloch, Xia Xu, Yan Zhou, Brenda Homony, Deborah A. Hepler, Hed...> ;Journal of Acquired Immune Deficiency Syndromes. 2018 Aug 15
• 185 citations
  Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy
  Lee T. Bacheler, Susan Jeffrey, George J. Hanna, Richard T. D'Aquila, Lany Wallace, Kelly Logue, Beverly C. Cordova, Kurt Hertogs, Brendan Larder, Renay Buckery, David...> ;Journal of Virology. 2001 Jun 1
• 5 citations
  Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receivi...
  Jean-Michel Molina, Yazdan Yazdanpanah, Alejandro Afani Saud, Christopher Bettacchi, Carolina Chahin Anania, Stephanie O Klopfer, Anjana Grandhi, Karen Eves, Deborah H...> ;Journal of Acquired Immune Deficiency Syndromes. 2022 Sep 1
• 17 citations
  Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a ph...
  Jean-Michel Molina, Yazdan Yazdanpanah, Alejandro Afani Saud, Christopher J. Bettacchi, Carolina Chahin Anania, Edwin DeJesus, Stephanie O. Klopfer, Anjana Grandhi, Ka...> ;The Lancet. HIV. 2021 Jun 1
• 8 citations
  Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study
  Tarik Asselah, Stanislas Pol, Christophe Hézode, Véronique Loustaud-Ratti, Vincent Leroy, Si Nafa Si Ahmed, Violaine Ozenne, Jean-Pierre Bronowicki, Dominique Larrey, ...> ;Liver International. 2020 Mar 22
• 45 citations
  Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority...
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;The Lancet. HIV. 2020 Jan 1
• Once-Daily Doravirine in HIV-1-Infected, Antiretroviral-Naive Adults: An Integrated Efficacy Analysis.
  Orkin, C.,Molina, J. M.,Lombaard, J.,DeJesus, E.,Rodgers, A.,Kumar, S.,Martin, E.,Hanna, G.,Hwang, C.> ;Clin. Infect. Dis.. 2019 May 24
• Once-Daily Doravirine for Initial Treatment of Adults Living With HIV-1: An Integrated Safety Analysis.
  Thompson, M.,Orkin, C.,Molina, J. M.,Sax, P.,Cahn, P.,Squires, K.,Xu, X.,Rodgers, A.,Kumar, S.,Teppler, H.,Martin, E.,Hanna, G.,Hwang, C.> ;Clin. Infect. Dis.. 2019 May 24
• Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
  Johnson, M.,Kumar, P.,Molina, J. M.,Rizzardini, G.,Cahn, P.,Bickel, M.,Mallolas, J.,Zhou, Y.,Morais, C.,Kumar, S.,Sklar, P.,Hanna, G. J.,Hwang, C.,Greaves, W.> ;J. Acquir. Immune Defic. Syndr.. 2019 Apr 16
• Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.
  Julg, B.,Dee, L.,Ananworanich, J.,Barouch, D. H.,Bar, K.,Caskey, M.,Colby, D. J.,Dawson, L.,Dong, K. L.,Dubé, K.,Eron, J.,Frater, J.,Gandhi, R. T.,Geleziunas, R.,Gould...> ;Lancet HIV. 2019 Mar 20
• Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection.
  Lawitz, E.,Poordad, F.,Anderson, L. J.,Vesay, M.,Kelly, M. M.,Liu, H.,Gao, W.,Fernsler, D.,Asante-Appiah, E.,Robertson, M. N.,Hanna, G. J.,Barr, E.,Butterton, J.,Kowdl...> ;J. Viral Hepat.. 2019 Feb 11
• 23 citations
  Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results...
  Lai Wei, Ji Dong Jia, Fu-Sheng Wang, Jun Qi Niu, Xu Min Zhao, Shengmei Mu, Li Wen Liang, Zaiqi Wang, Peggy Hwang, Michael N. Robertson, Paul Ingravallo, Ernest Asante-...> ;Journal of Gastroenterology and Hepatology. 2018 Dec 9
• Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immun...
  Orkin, C.,Squires, K. E.,Molina, J. M.,Sax, P. E.,Wong, W. W.,Sussmann, O.,Kaplan, R.,Lupinacci, L.,Rodgers, A.,Xu, X.,Lin, G.,Kumar, S.,Sklar, P.,Nguyen, B. Y.,Hanna,...> ;Clin. Infect. Dis.. 2018 Sep 06
• Viral Drug Resistance through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
  Lataillade, M.,Zhou, N.,Joshi, S. R.,Lee, S.,Stock, D. A.,Hanna, G. J.,Krystal, M.> ;J. Acquir. Immune Defic. Syndr.. 2017 Dec 06
• 20 citations
  Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized...
  Melanie Thompson, Jacob Lalezari, Richard Kaplan, Yvett Pinedo, Otto A Sussmann Pena, Pedro Cahn, David A. Stock, Samit R Joshi, George J. Hanna, Max Lataillade, Ai st...> ;Antiviral Therapy. 2016 Apr 1
• Join now to see all

Journal Articles

• Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Is Non-Inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive Adults with Human Immun...  
  George J Hanna, Peter Sklar, Kathleen E Squires, Paul E Sax, Carey Hwang, Clinical Infectious Diseases